Cranberry is one of the longest-studied botanical ingredients in the urinary-health category, and its active compounds — proanthocyanidins, or PACs — give brands abroad a specific, well-researched reason to ask for a Japan-made cranberry product.
This guide is for brand owners planning a cranberry product made in Japan. It sets out what a large, recently updated Cochrane review actually found, why the result depends heavily on which population is being studied, Japan’s food status for the ingredient, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a cranberry product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 2023 Cochrane review of 50 trials found that cranberry products reduced the risk of urinary tract infection overall, with clearer benefit in women with recurrent infections and in children, but little or no benefit in elderly institutionalised people or pregnant women.
| Study | Design/What was analysed | Reported result |
|---|---|---|
| Cochrane systematic review, Cochrane Database of Systematic Reviews 2023 (PMID 37947276) | 50 randomised controlled trials, 8,857 participants, cranberry products versus placebo, water, no treatment, probiotics or antibiotics, across six population groups | Moderate-certainty evidence that cranberry reduced symptomatic, culture-verified urinary tract infection risk overall (RR 0.70); benefit was clearer in women with recurrent infections (RR 0.74), children (RR 0.46) and people made susceptible by a medical intervention (RR 0.47); little or no benefit in elderly institutionalised men and women (RR 0.93), pregnant women (RR 1.06) or adults with neuromuscular bladder dysfunction (RR 0.97) |
| Randomised, double-blind, placebo-controlled ex vivo study, Natural Product Communications 2015 (PMID 26411014) | Healthy men and women given a single dose of one of three cranberry extracts, each standardised to 36 mg PACs by the BL-DMAC method, or placebo | Urine collected 6–12 hours after intake showed significantly increased anti-adhesion activity against uropathogenic P-fimbriated E. coli for all three extracts compared with placebo |
The same review found that gastrointestinal side effects did not differ meaningfully between cranberry and placebo groups, and that it remains unclear whether efficacy differs between cranberry juice and tablets, or between different PAC doses, because the certainty of evidence on those specific comparisons was very low.
Three points worth keeping in view:
- The result depends on who is studied. The 2023 review is explicit that benefit varies sharply by population — clear in some groups, absent in others. A single average result across all 50 trials would misrepresent the evidence.
- Dose and format are not settled. The review notes there is no established regimen for PAC dose, and that processing cranberries into tablets or capsules can strip out much of the PAC content, so products can vary widely in what they actually contain.
- This is a large, current, high-quality body of evidence. Fifty trials and nearly 9,000 participants, updated as recently as November 2023, is one of the stronger evidence bases among botanical ingredients covered in this series — a reason for precision in wording, not for overstatement.
Checked against the published abstract on 25 September 2026.
What Japanese products say
Cranberry fruit and leaf sit on the Japanese list of ingredients not judged to be medicines unless a medicinal claim is made, which is why cranberry is sold in Japan as a general food ingredient.
Japan’s food-drug classification system (食薬区分) maintains a list of substances treated exclusively as medicines and a separate list of substances not judged to be medicines provided the product does not claim a medicinal effect. Cranberry (クランベリー, also known as ツルコケモモ), fruit and leaf, sits on the non-medicinal list. That status is why cranberry juice, extract and supplement products are widely sold in Japan through ordinary food retail channels.
Being food-usable is a separate question from carrying a notified function. A Japanese company wishing to state a specific function for a cranberry product under the Foods with Function Claims system would need its own notification and its own supporting evidence for that exact product.
💬 Need an evidence summary for your regulatory adviser that reflects which population groups the research actually supports? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe cranberry by its PAC content and what has been studied in which group, never as a treatment for a urinary infection.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for urinary comfort in specific population groups" | "Prevents”, “treats” or “cures” urinary tract infections |
| ”Contains cranberry extract standardised to a stated PAC content” | Naming a disease or a specific patient population as a product claim |
| Naming the review and its finding that benefit varies by group | ”Clinically proven” without noting the population and PAC content it applies to |
How cranberry is formulated
Cranberry’s low natural PAC concentration and the ease of losing PAC content during processing make the extract standardisation the central specification decision.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule | Simple, standard for a standardised dry extract | PAC content varies widely between suppliers; standardisation must be specified |
| Tablet | Familiar, stable format | Binder choice for a concentrated fruit extract |
| Powder or granule | Fits into drinks and combination products | Colour and taste from the fruit extract |
Decisions that shape the specification:
- PAC standardisation. Ask the supplier for the PAC content, the analytical method used to measure it (commonly the DMAC method), and whether the material is a juice concentrate, a whole-fruit powder, or a PAC-standardised extract — these differ substantially in actual PAC delivered per serving.
- Amount per serving. The 2023 Cochrane review notes there is no established PAC dose regimen; match your amount to a specific study if you plan to cite one, and be aware the certainty of evidence on dose comparisons is very low.
- Population fit. If you plan to reference the research at all, be precise about which population group the cited result applies to.
- Companion ingredients. Cranberry is often combined with other “urinary comfort” botanicals such as D-mannose or hibiscus. Each companion ingredient needs its own check against Japanese food law.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Cranberry itself is well established in Japanese foods. Companion botanicals in combined urinary-comfort formulas are where a check most often turns up a problem. See the Japan-made supplement OEM page, and compare with our dietary fibre and nattokinase guides.
Before you ask for a quotation
A factory can quote accurately once the PAC standardisation, the amount, the form and the companions are fixed.
- Cranberry material type (juice concentrate, whole-fruit powder or PAC-standardised extract) and PAC content
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made cranberry product? Send us the concept — PAC standardisation, amount, form and the countries you will sell in.
Frequently asked questions
1. Does cranberry prevent urinary tract infections?
A 2023 Cochrane review of 50 trials found cranberry products reduced infection risk overall, with clearer benefit in women with recurrent infections, children, and people made susceptible by a medical intervention, but little or no benefit in elderly institutionalised people or pregnant women. Describe it as studied for urinary comfort in specific groups, not as a preventive treatment.
2. Why do cranberry products vary so much in effectiveness?
The Cochrane review notes that processing cranberries into tablets or capsules can strip out much of the PAC content, and there is no established dose regimen, so two products both labelled “cranberry” can deliver very different amounts of the active compound.
3. Is cranberry juice better than cranberry tablets?
The 2023 review found it unclear whether efficacy differs between cranberry juice and tablets, because the certainty of evidence on that specific comparison was very low.
4. Is cranberry legal to sell as a food in Japan?
Yes. Cranberry fruit and leaf sit on Japan’s list of ingredients not judged to be medicines unless a medicinal claim is made, which is why cranberry products are widely sold there as foods.
5. Are gastrointestinal side effects common with cranberry?
The 2023 Cochrane review found no meaningful difference in gastrointestinal side effects between cranberry and placebo groups across the trials it reviewed.
Sources: “Cranberries for preventing urinary tract infections”, Cochrane Database of Systematic Reviews 2023 (PMID 37947276); “Comparison of the Anti-Adhesion Activity of Three Different Cranberry Extracts on Uropathogenic P-fimbriated Escherichia coli: a Randomized, Double-blind, Placebo Controlled, Ex Vivo, Acute Study”, Natural Product Communications 2015 (PMID 26411014); Japan Ministry of Health, Labour and Welfare 食薬区分における成分本質（原材料）の取扱いの例示. Checked on 25 September 2026.